A while back we blogged about the arrival of Xeomin (incobotulinumtoxinA), the newest neurotoxin, and competitor to Botox and Dysport, which received its FDA approval in 2011 to treat the glabella region. Last year, an injunction was filed by Allergan (the makers of Botox) claiming trade secrets had been stolen from them during this process.
The injunction has finally been lifted and Xeomin will hit the market again soon and Merz (the manufacturer) will begin promoting it nationally. Dr. Rueckl and Lakes Dermatology will continue to do our research to make certain this product is as good as other neurotoxins on the market and make decisions about whether we will offer this service, as more information becomes available.
